Skip to main content

Table 1 Health resource utilisation considered in derivation of cost of HCV Health-states

From: Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study

Input

Mild

Mod

Comp. Cirrhosis

Decomp. Cirrhosis

HCC

Transplant Year 1

Transplant > Year 1

SVR

Source

OPD bundlea

Institution costs

 FBC

         

 Renal profile

         

 Liver profile

         

 Coagulation screen

         

 AFP

         

 HCV Viral load

         

 Liver US

         

 Staff Costs

        

HSE salary scale 2010

Liver Biopsy

HSE DRG 2011

OGDb

HSE DRG 2011

Hepatology Medical review

Micro-costing

Hepatology Nursing review

Micro-costing

Inpatient Admission

HSE DRG 2011

Sorafenib

Micro-costingd

TACEc

Institution cost

Oncology/ Palliative OPD

HSE DRG 2011

Dermatology OPD

HSE DRG 2011

Hepatology Dayward review

HSE DRG 2011

Pre-transplant workup

Micro-costing

3 months Prophylaxis

Micro-costingd

Immunosuppression

Micro-costingd

Diuretic/Beta-blocker

Micro-costingd

  1. Mod moderate, Comp. cirrhosis Compensated cirrhosis, Decomp. Cirrhosis decompensated cirrhosis, HCC hepatocellular carcinoma, Transplant Year 1 First 12 months of liver transplantation, Transplantation > Year 1 Transplantation After First 12 months, SVR Sustained Viral Response, HSE Health Service Executive, DRG Diagnostic Related Group, PCRS Patient Care Reimbursement Service, OPD outpatient, aBundle: FBC Full Blood Count, Renal Profile Urea, Creatinine, Sodium, Potassium, Bicarbonate; Liver Profile Albumin, Alanine amino transaminase, Aspartate amino transaminase, Gamma glutamyl transferase, Bilirubin, Lactate Dehydrogenase; Coagulation Screen Prothrombin Time, Activated partial thromboplastin time, International Normalised Ratio, AFP Alpha fetoprotein, bOGD Oesophago-gastro-duodenoscopy, cTACE Transarterial chemoembolisation, dUnit cost of drug sourced from the Primary Care Reimbursement System